|stock ticker: CHE|
Chemed: Game Over
Citron details the breaking news defining the looming regulatory and litigation threat at Chemed (NYSE:CHE) the analysts won’t identify.
Citron is very familiar with Medicare fraud from the Amedisys days. Here we provide links to the breaking news, including the pivotal case documents the company should disclose and the analysts haven't mentioned.
Price target : $15.00.
( As always, Citron recommends you download the PDF, and right-click to open the relevant links.)
|stock ticker: ANGI|
Angie's List (NASDAQ:ANGI) is hands down the most ridiculous business model in the new web economy.
Part 1 of Citron's expose will detail the fundamentals of the business.
Part 2 will focus on the many accounting tricks used by Angie's to show how they lose less money than they really do.
Long term, it is Citron’s firm opinion that this stock is a definite zero …Short term, Citron shows a compelling valuation comparison that would value ANGI, in a best case scenario, at $5 to $6 a share.
(Citron recommends you download this .PDF, read it locally and right-click to follow the links the new windows or tabs.)